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Abstract 
Objective: We assessed the influence of age on warfarin dose, percent time in target range 
(PTTR), and risk of major hemorrhage.  
Design: Warfarin users recruited into a large prospective inception cohort study were 
categorized into three age groups: young (<50 years), middle-aged (50 -70 years), and elderly 
(>70 years). The influence of age on warfarin dose and PTTR was assessed using regression 
analysis and risk of major hemorrhage was assessed using the proportional hazards (PH) 
analysis. Models were adjusted for demographic, clinical and genetic factors. 
Setting: Two outpatient anticoagulation clinics 
Participants: 1498 anticoagulated patients 
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Outcomes: Warfarin dose (mg/day), PTTR, major hemorrhage 
Results: Of the 1498 patients, 22.8% were young, 44.1% were middle-aged, and 33.1% were 
elderly. After accounting for clinical and genetic factors, compared to young warfarin users, 
warfarin dose requirements were 10.6% lower among the middle-aged and an additional 
10.6% lower for the elderly. Compared to young patients, middle-aged and elderly patients 
spent more time in target INR range (p<0.0001), despite having fewer INR assessments 
(p<0.0001). Compared to young warfarin users, absolute risk for hemorrhage was marginally 
higher among middle-aged (p=0.08) and significantly higher among the elderly (p=0.016). 
Compared to young warfarin users, after adjustment, the relative risk of hemorrhage 
increased by 31% for each age category (p=0.026). 
Conclusions: In a real-world setting, despite achieving better anticoagulation control, elderly 
patients had a higher risk of major hemorrhagic events. As the population ages and the candidacy 
for oral anticoagulation increases, strategies that mitigate the elevated risk of hemorrhage need to 
be identified.  
 
 
Introduction 
Oral anticoagulants are the main treatment modality for decreasing the risk of venous 
thromboembolism and thromboembolic events associated with atrial fibrillation.1 Despite the 
introduction of non-vitamin K antagonists (DOACs), warfarin remains the most widely used oral 
anticoagulant in the US.2, 3 Warfarin dosing has remained challenging because of its pronounced 
inter-individual variability, narrow therapeutic index, drug and dietary interactions,4 and potential 
for over-anticoagulation leading to hemorrhagic complications.5-7 Thus, despite being efficacious, 
warfarin is underutilized, 8, 9 due in part to fear of bleeding episodes.10 Anticoagulation related 
bleeding is a frequent cause of adverse drug related hospitalizations in the US.11  
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Increasing age is an important predictor of dose and a non-modifiable risk factor for 
hemorrhage.12-15 As the population ages, the need for anticoagulation is expected to increase with 
the rise in age-related comorbidities. For instance, the prevalence of atrial fibrillation (AF), the most 
common dysrhythmia, increases with age and is expected to reach 12.1 million by 2030.16-18 
Additionally, patients with AF are five times more likely to experience an ischemic stroke and twice 
as likely to die compared to patients without AF.19, 20 Therefore, the need for safe and effective 
anticoagulation in an aging population is of paramount importance. To this end, we examined the 
effect of age on dose, anticoagulation control, and major hemorrhagic events in warfarin users after 
accounting for clinical and genetic variables. 
Methods 
Study Population 
Participants (>20 years old) initiating warfarin with the target international 
normalized ratio (INR) of 2.0-3.0 were enrolled at the beginning of treatment in an inception 
cohort under the approval of the Institutional Review Boards of the University of Alabama at 
Birmingham and Emory University. Patients requiring a target INR of 2.5-3.5 (e.g. 
mechanical heart valves) were excluded.21, 22 
Clinical and Genetic Variables 
Patients managed at two oral anticoagulant clinics were approached and consented for 
enrollment in the study. Patient history was collected through a structured interview form and 
included information on demographics, indications for therapy, comorbidities, and 
medications as previously reported.21-23 Information on factors related to lifestyle and socio-
economic status including smoking, alcohol use, physical activity, dietary vitamin K intake, 
education, annual household income, and medical insurance was also collected. Medical 
records were reviewed to verify the medical history of the patients. 
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Follow-up included monthly visits for up to two years from initiation of therapy. 
Information on factors that affect warfarin response were collected during these visits, and 
included INR, concurrent medications, dietary vitamin K intake, alcohol use, and physical 
activity. Medication information was verified by medical record review as before, with 
emphasis on drugs that alter warfarin response, including non-steroidal anti-inflammatory 
drugs, antiplatelet agents, and CYP2C9 inhibitors, inducers, or substrates. 
 
  In addition to clinical data, patients were genotyped for warfarin-specific 
polymorphisms.21, 22 Blood samples were collected during the enrollment visit, and DNA 
extracted using the Gentra PureGene system (Gentra Sys, Inc. Minneapolis, MN). VKORC1 
(rs9923231), CYP2C9 [*2 (rs1799853), *3 (rs1057910)], CYP4F2 (rs2108622), African 
American specific CYP2C9 Single Nucleotide Polymorphisms (SNPs) [*5 (rs28371686), *6 
(rs9332131), *11 (rs28371685)], and the CYP2C SNP rs12777823 were genotyped. 21-26 
 
Outcome definitions 
Warfarin dose (mg/day; log transformed to attain normality) was defined as the average 
maintenance dose after the attainment of three consecutive INRs in target range measured at 
least 2 weeks apart, as previously defined.24, 25, 27, 28 
 
Proportion of time spent in target range (PTTR) and quality of anticoagulation control: For 
each patient, PTTR was calculated as the percentage of interpolated INR values within the 
target range of 2.0–3.0 after attainment of first INR in target range using the Rosendaal linear 
interpolation method.29 We also present proportion of time spent below (PTBR) and above 
(PTAR) target range.  
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Because PTTR is a recognized risk factor for hemorrhage, we categorized patients’ 
quality of anticoagulation control based on cumulative PTTR in two ways. First, we 
considered PTTR ≥60% (vs. <60%) because this has been evaluated as a predictor of 
hemorrhage in warfarin users in recent clinical trials and has also been included in the 
recently proposed HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, 
Bleeding history, Labile INR (defined as PTTR<60%), Elderly, Drug consumption/alcohol 
abuse) score.30 Second, as the effectiveness of warfarin compared to the newer oral 
anticoagulants is related to the level of PTTR achieved, we also categorized PTTR as poor 
anticoagulation control (PTTR <60%), good control (60≤PTTR<70), and excellent control 
(PTTR ≥70).31-34  
 
Major Hemorrhage: As previously defined,35 major hemorrhages included fatal bleeding; 
and/or symptomatic bleeding in a critical area or organ, such as intracranial, intra-spinal, 
intraocular, retroperitoneal, intra-articular, or pericardial, or intramuscular with compartment 
syndrome; and/or bleeding with a fall in hemoglobin level of ≥2 gm/dL, or leading to 
transfusion of ≥2 units of whole blood or red cells. As the focus of this manuscript was to 
evaluate the association of age on risk of major hemorrhages, minor hemorrhages (mild 
nosebleeds, microscopic hematuria, mild bruising, and mild hemorrhoidal bleeding) were not 
included in the analysis. During the 2-year follow-up, for all major hemorrhagic 
complications, the complication site (e.g. endoscopy of gastrointestinal tract), severity of the 
event (e.g. requiring transfusion, surgical intervention), and laboratory findings (e.g. INR, 
hemoglobin/hematocrit) at the time of the event were objectively documented. Isolated sub-
therapeutic or supra-therapeutic INRs in the absence of evidence of bleeding were not 
classified as events. The Alabama Center for Health Statistics was queried to verify cause of 
death for all deceased to ensure inclusion of deaths due to hemorrhagic complications. All 
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complications were adjudicated independently by the Medical Director of the 
Anticoagulation Clinic. Only medically documented, adjudicated events were included in the 
analyses, as previously reported.27, 36-38 
 
Statistical Analyses 
Analysis of variance was used to assess group differences for continuous variables 
and chi-square for categorical variables. All SNPs were tested for the Hardy-Weinberg 
Equilibrium assumption by calculating the allele as well as genotype frequencies and using a 
chi-square exact test.  
 
First, we evaluated the univariate association of age with warfarin dose, PTTR, and 
risk of hemorrhage. These results informed the age-categorization for subsequent adjusted 
analyses as young (<50), middle-aged (50-70) and elderly (>70). We then evaluated the effect 
of age (young, middle-aged, elderly) on warfarin dose and PTTR using multivariable linear 
regression analysis. The influence of age on the risk of major hemorrhage was assessed using 
the counting process format in the proportional hazards (PH) model. The models were 
adjusted for demographic [ i.e. gender, race, body mass index (BMI)], lifestyle (i.e. smoking), 
clinical comorbid conditions [i.e. kidney impairment (categorized as estimated glomerular 
filtration rate eGFR >60, 30-59, <30ml/min/1.73 m2)], medication use (i.e. antiplatelet), or 
genetic (i.e. CYP2C9, CYP4F2, VKORC1 and rs12777823) factors. We included factors that 
showed significant differences in prevalence by age in our cohort and retained these factors in 
the model at a nominal p-value of <0.2. All analyses were performed using SAS version 9.3 
at a non-directional alpha level of 0.05. 
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Role of the funding source 
The study was funded by the National Institutes of Health, but the funders had no role 
in the study design, data collection, data analysis, interpretation of results, or writing of this 
manuscript.  
 
Results 
Of the 1498 patients (48% women, 44% African American) included in the analysis, 
341 (23%) were below the age of 50 years (young), 661 (44%) were between the ages of 50 
and 70 years (middle-aged) and 496 (33%) were more than 70 years of age (elderly). 
Participant characteristics by age groups are shown in Table 1.  
 
Compared to young warfarin users, the middle-aged and elderly patients had lower 
warfarin dose requirements (p<0.0001) and lower eGFR (p<0.0001). When compared to 
younger and middle-aged groups, the elderly group consisted of a significantly higher 
proportion of women (p=0.048) and European Americans (p<0.0001), and were more likely 
to be on warfarin due to atrial fibrillation (p<0.0001). The younger patients were more likely 
to be African American and be on warfarin for venous thromboembolism (p<0.0001). The 
prevalence of hypertension (p<0.0001), hyperlipidemia (p<0.0001), diabetes (p<0.0001), and 
heart failure (p=0.0026) increased with age. The elderly had the highest prevalence of stage 3 
chronic kidney disease (CKD) (eGFR 30 -59ml/min/1.73m2) and the lowest prevalence of 
end stage renal disease (eGFR<30 ml/min/1.73m2). Similarly, the concurrent use of statins 
(p<0.0001), antiplatelet agents (p<0.0001), and amiodarone (p=0.001) was highest among the 
elderly. The assumption of Hardy Weinberg Equilibrium was met for all SNPs (p>0.20). The 
prevalence of genetic factors known to influence warfarin response did not vary by age group 
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except for the VKORC1 (p<0.0001) and CYP2C9*3 variants (p=0.01), which were more 
prevalent in the elderly.  
 
After accounting for clinical and genetic factors, compared to young patients, 
warfarin dose requirements were 10.6% lower among the middle-aged and an additional 
10.6% lower for the elderly patients. Gender did not influence warfarin dose requirements. 
Warfarin dose requirements were lower among patients possessing CYP2C9, VKORC1 and 
rs12777823 variant, among African Americans, in patients with CKD, congestive heart 
failure (CHF) and those on concurrent amiodarone therapy. On the other hand, higher BMI, 
venous thromboembolism and possession of the CYP4F2 variant were associated with higher 
warfarin dose requirements. The final dosing algorithm by age after incorporating clinical 
and genetic factors is presented in Table 2. 
 
Overall PTTR in the study cohort was 52.4% (±22.5%). Young patients spent more time below 
range (PTBR, p<0.0001) compared to the middle-aged and elderly (Table 3, Figure 1a). Compared to 
young patients, middle-aged and elderly patients spent more time in target INR range (p<0.0001), 
despite having fewer INR assessments per month (1.78 ± 1.52 vs. 1.35 ± 1.19 vs. 1.24 ± 1.74 
visit/month, p<0.0001). Patients achieving a PTTR≥ 60% over the treatment period are considered to 
have good anticoagulation control and those achieving a PTTR≥ 70% are considered to have 
excellent anticoagulation control. Young warfarin users were less likely to achieve these metrics for 
anticoagulation control compared to the middle-aged (p<0.0001) and elderly (p<0.0001) warfarin 
users (Table 3, Figure 1b). 
 
Over 2050 person-years of follow-up, 173 major hemorrhagic events were 
encountered [incidence rate (IR): 8.44; 95% CI: 7.25-9.77]. Major hemorrhages by site 
included gastrointestinal (n=104), genitourinary (n=22), retroperitoneal (n=7), intracranial 
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bleeds (n=15), hemoptysis (n=5), and hematomas (n=20). Incidence rates were lowest in the 
young warfarin users and highest among the elderly (Table 3). Compared to young warfarin 
users, the incidence rate ratio (IRR) of hemorrhage was marginally higher among middle-
aged (IRR: 1.5; 95% CI 0.95-2.56; p=0.08) and significantly higher among the elderly (IRR: 
1.8; 95% CI 1.12-3.0; p=0.016). 
 
After adjusting for race, gender, BMI, hypertension, chronic kidney disease, PTTR 
(<60 vs. >60%), genetic factors, concurrent antiplatelet, amiodarone and statin therapy, the 
risk of hemorrhage increased by 31% for each age category (HR= 1.31 95% CI 1.03-1.66; 
p=0.026; Figure 1c) when compared to young warfarin users. In addition to older age, 
African American race (HR= 1.49 95% CI 1.02-2.17; p=0.04), concomitant antiplatelet 
therapy (HR= 1.64; 95% CI 1.14-2.36; p=0.008), hypertension (HR= 1.70; 95% CI 1.07-2.71; 
p=0.025), CKD (HR= 1.49; 95% CI 1.15-1.96; p<0.0001), PTTR<60% (HR= 2.27; 95% CI 
1.51-3.42; p<0.0001), and possession of CYP2C9*3 variant (HR=1.7; 95% CI 1.0- 2.9; 
p=0.05) were associated with an increased risk of hemorrhage. 
 
Discussion 
We present a comprehensive look at warfarin response among young (<50), middle-aged 
(50-70), and elderly (>70) warfarin users from a large prospective cohort study. We demonstrate 
that middle-aged patients need a 10% warfarin dose reduction and the elderly need an additional 
10% warfarin dose reduction after accounting for clinical and genetic factors. Assessment of 
anticoagulation control (PTTR) showed that middle-aged and elderly patients have better 
anticoagulation control as compared to young warfarin users, and a higher proportion of these 
patients also achieve good (PTTR>60%) and excellent control (PTTR>70%). Furthermore, evaluation 
of the age-hemorrhage association indicated that elderly patients have a higher risk of major 
hemorrhage despite achieving better anticoagulation control. 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
 
Our study found a significant inverse association between age and warfarin dose, a finding 
that is consistent with existing literature.12-15 Warfarin dose reductions in prior studies have ranged 
from 8% to 21% per decade of life, whereas evaluation of age on a continuous scale has been shown 
to result in a weekly warfarin dose decrease of 0.4 mg per year of aging.12-15 Thus, older patients are 
more sensitive to warfarin compared to younger patients. Age related changes in drug response are 
multifactorial with decline in clearance, albumin binding, or renal excretion contributing to 
pharmacokinetic changes.38-40 Moreover, the increase in comorbid conditions and concomitant 
medication use in the elderly may influence warfarin response in complex ways through drug-drug 
and drug-disease interactions. This is illustrated by the multitude of factors that influence warfarin 
dosing, several of which are now included in the warfarin dosing algorithm. 
 
Several factors significantly associated with warfarin dose in the current study are also part 
of the commonly used warfarin dosing algorithm listed above and have been established as 
important predictors of warfarin dose and response. Our own research group has previously 
reported on the associations of kidney function,25 left ventricular systolic dysfunction,41 and the 
CYP2C9,21, 22 VKORC1,22, 23 and CYP4F2 27 variants with warfarin dose. We also recently evaluated the 
differential effect of self-reported race on warfarin, reporting on the variable effect of genetic and 
non-genetic factors on warfarin dose and hemorrhage by race.28, 36 However, the effect of age on 
warfarin dose was similar across race groups in our study. 32  
 
Age is also an important predictor of bleeding outcomes among warfarin users, and 
has been incorporated into several bleeding risk scores.30, 42-44 However, comparison of the 
different scores show variability in classification across risk categories and only modest 
improvements in the ability to predict bleeding outcomes.45, 46 Moreover, the age cut-off 
across these models are not consistent, making it difficult to establish a fixed age threshold 
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for assessing bleeding risk. The recent evaluation by Senoo et al. demonstrated that the HAS-
BLED score performed better compared to the ATRIA or ORBIT scores because it 
incorporates PTTR. 50 A significant body of evidence exists which supports that poor 
anticoagulation control (PTTR<60%) is a predictor for hemorrhage among warfarin users.31-
34
 Moreover, PTTR≥60% is widely recognized as the accepted quality metric for 
anticoagulation management services and is incorporated into risk prediction rules. The 
consistency of the influence of PTTR on risk of hemorrhage was also demonstrated in the 
recent DOAC clinical trials. 34, 47 For instance, compared to dabigatran (150 mg dose), the 
risk of hemorrhage was higher for warfarin users with PTTR <57%, similar among warfarin 
users with PTTR 57-72%, and lower among those with PTTR>72%.34 In our study, older 
patients had significantly higher PTTR compared to younger patients but also had a higher 
risk of major hemorrhagic events despite attaining better anticoagulation control. Sanden et 
al. demonstrated that at very high PTTR (>70), where almost all patients have achieved 
therapeutic INR of 2.0-3.0, PTTR was not correlated to warfarin-related complications in 
patients with AF.48 In this scenario, it is possible that factors other than PTTR such as poor 
hypertension control may be responsible for the high hemorrhagic risk. Another possible 
explanation may be age-related frailty where the deterioration in normal bodily functions play 
a role in precipitating adverse outcomes.49,50 Although aiming for a lower INR target range 
(1.6 to 2.6) in patients over the age of 70 may reduce the bleeding risk,51, 52 it may also limit 
effectiveness.53 Based on current evidence, the benefits of warfarin therapy (INR 2-3) still 
outweigh the risks even in elderly patients.8, 54 
 
Although this is a large prospective inception cohort study, we recognize its limitations. It 
was neither feasible nor possible to control for all potential confounders such as over-the-counter 
medication use, episodic use of antibiotics, dietary vitamin K intake, rare genetic variants, and gene-
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gene, gene-environmental interactions. Given the efficacy of warfarin, the incidence of 
thromboembolic events among patients on warfarin in our cohort was low. As a result, we were 
unable to assess the benefit vs. risk of warfarin across the three age categories. However, 
anticoagulation control can serve as a practical surrogate for the actual thromboembolic events as it 
is always the goal for any anticoagulation therapy to attain target INR. All patients in our study were 
able to achieve a target INR of 2.0-3.0, however, this prevented us from assessing whether a lower 
INR range would result in a lower risk of hemorrhage. Finally, as in all observational studies, caution 
in ascribing the observed effects as causal is prudent. 
 
Conclusion 
Despite achieving better anticoagulation control, elderly patients on warfarin had a higher 
risk of major hemorrhagic events as compared to younger patients. Strategies to mitigate the 
hemorrhagic risk while maintaining the risk reduction in thromboembolic events are needed. As the 
population ages and the candidacy for oral anticoagulation increases, identifying reliable strategies 
that enable protection against adverse bleeding events would be impactful. 
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Table 1. Characteristics of the participants categorized by age 
 
Footnote to table 1: SD: Standard Deviation 
aAll eGFR are based on National Kidney Foundation staging using the Modification of Diet in Renal 
Disease Study equation. Patients were categorized into 3 categories: GFR >60 (no CKD or mild CKD 
stage 1 and 2), GFR=30-59 (moderate CKD; stage 3) and GFR<30 (severe CKD; stage 4 and 5). 
bStatins included any of the HMG-COA reductase inhibitors. 
cConcurrent antiplatelet agents included aspirin, clopidogrel, and dipyridamole as mono or dual 
therapy.  
dGenotype information was not available in 93 patients for CYP2C9, 45 patients for VKORC1, 197 for 
CYP4F2 and 198 for rs12777823 as these samples had not been genotyped. The VKORC1 variant (-
1639 C>T) includes ‘TT or CT’, CYP4F2 variant includes ‘AG or AA’, and rs12777823 variant includes 
‘AG or GG’. 
 
Table 2. Warfarin dose requirements by age (<50, 50-70, and >70 years) after accounting for 
clinical and genetic factors 
 
Footnote to table 2: CI: confidence intervals, BMI: Body Mass Index 
aThe referent is a white male, 50 years or younger with BMI centered at 25 kg/m2, without chronic 
kidney disease, venous thromboembolism or heart failure (left ventricular ejection fraction <55%), 
not on concurrent Amiodarone or statin therapy, with wild-type genotype for CYP2C9, VKORC1, 
CYP4F2, and rs12777823. 
 
 
Table 3. Influence of age (<50, 50-70, and >70 years) on indices of anticoagulation control, and 
incidence of hemorrhage 
 
Footnote to table 3: PTBR: Percent Time spent Below target INR Range, PTTR: Percent Time spent in 
Target INR Range, PTAR: Percent Time spent Above Target INR Range, CI: confidence intervals. 
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Table 1: Characteristics of the participants categorized by age 
Characteristics Age < 50 Age 50-70 Age >70 
n=341 n=661 n=496 
Mean ± SD Mean ± SD Mean ± SD 
Mean Age 38.6 ± 8.1 60.0 ± 5.7 77.8 ± 5.6 
Body mass index (BMI) 30.8 ± 8.5 31.3 ± 8.0 28.3 ± 6.1 
Hematocrit, % 36.7 ± 13.3 37.1 ± 6.7 37.2 ± 6.5 
Glomerular filtration rate (eGFR) 80.1 ± 38.2 67.5 ± 28.2 61.1 ± 21.6 
Dose (mg/day) 6.8 ± 2.8 5.7 ± 2.4 4.6 ± 2.0 
N (%) N (%)  
Female 172 (50.4%) 297 (44.9%) 257 (51.8%) 
Race    
European American 138 (40.5%) 353 (53.4%) 337 (67.9%) 
African American 197 (57.8%) 302 (45.9%) 156 (31.5%) 
Other 6 (1.7%) 6 (0.7%) 3 (0.6%) 
Indication for Warfarin therapy    
Venous thromboembolism 231 (67.7%) 283 (42.8%) 140 (28.2%) 
Atrial Fibrillation 38 (11.1%) 267 (40.4%) 315 (63.5%) 
Stroke / Transient Ischaemic Attack 21 (6.2%) 33 (5.0%) 25 (5.0%) 
Other 51 (17.9%) 77 (11.6%) 15 (3.0%) 
Comorbid conditions    
Hypertension 146 (44.4%) 470 (71.5%) 376 (76.0%) 
Hyperlipidemia 66 (20.1%) 352 (55.6%) 298 (60.2%) 
Diabetes Mellitus 63 (19.1%) 254 (38.9%) 159 (32.1%) 
Congestive Heart Failure 68 (20.2%) 186 (28.3%) 122 (24.6%) 
Chronic Kidney Diseasea    
eGFR ≥60ml/min/1.73m2 255 (75.2%) 430 (65.5%) 247 (50.2%) 
eGFR 30 -59ml/min/1.73m2 45 (13.3%) 160 (24.4%) 217 (44.1%) 
eGFR < 30 ml/min/1.73m2 39 (11.5%) 217 (44.1%) 28 (5.7%) 
Concurrent medications     
Statinsb 95 (28.2%) 412 (62.7%) 308 (62.2%) 
Antiplatelet agentsc 133 (36.5%) 418 (63.6%) 338 (68.3%) 
Amiodarone 17 (5.0%) 76 (11.6%) 62 (12.5%) 
Genetic factorsd    
CYP2C9 *2 variant 39 (13.6%) 94 (16.7%) 75 (17.9%) 
CYP2C9 *3 variant 15 (5.2%) 41 (7.3%) 47 (11.2%) 
CYP2C9*5 or *6 or *11  8 (2.8%)  8 (1.4%)  3 (0.7%) 
VKORC1 (-1639C/T) 
Wild-type 
Variant 
198 (66.9%) 
 98 (33.1%) 
336 (59.1%) 
232 (40.9%) 
 
217 (50.1%) 
216 (49.9%) 
CYP4F2 variant  90 (32.5%) 193 (35.2%) 170 (41.5%) 
rs12777823 101 (36.5%) 186 (34.0%) 152 (37.0%) 
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Table 2: Warfarin dose requirements by age (<50, 50-70, >70 years) accounting for the 
effect of genetic and clinical factors 
Variable Effect on Warfarin Dose (95% CI) 
Dose (mg/day) % Dose Change P-value 
White male < 50 yearsa 8.1 (7.5 to 8.8)    
50-70 years 7.2 (6.3 to 8.3) -10.6 (-15.8 to -5.2)  0.0002 
> 70 years 7.2 (6.3 to 8.3) -10.6 (-15.1 to -5.9) <0.0001 
African American 7.6 (6.6 to 8.7) -6.2 (-11.3 to -0.9)  0.02 
Female 7.9 (6.9 to 9.0) -2.2 (-6.9 to 2.8)  0.39 
BMI centered at 25 kg/m2 9.0 (8.1 to 10) 11.3 (8.7 to 14.0) <0.0001 
Chronic Kidney disease 7.5 (6.7 to 8.5) -6.8 (-9.9 to -3.6) <0.0001 
Venous thromboembolism  8.4 (7.4 to 9.6) 4.3 (-0.7 to 9.6)  0.09 
Congestive Heart Failure 7.6 (6.6 to 8.7) -6.6 (-11.5 to -1.5)  0.012 
Concurrent amiodarone use 6.4 (5.5 to 7.5) -20.6 (-26.1 to -14.6) <0.0001 
Statin Use 7.8 (6.8 to 8.8) -4.0 (-8.4 to 0.6)  0.08 
CYP2C9 *2 6.6 (5.8 to 7.6) -18.3 (-22.7 to -13.6) <0.0001 
CYP2C9 *3  6.8 (4.5 to 6.2) -34.7 (-39.5 to -29.6) <0.0001 
CYP2C9 *5 or *6 or *11 6.0 (5.2 to 8.7) -16.5 (-29.8 to -0.6)  0.04 
VKORC1  8.4 (5.3 to 6.7) -26.1 (-28.8 to -23.3) <0.0001 
CYP4F2  6.0 (7.4 to 9.5) 3.7 (-0.3 to 7.8)  0.07 
rs12777823 7.4 (6.5 to 8.4) -8.6 (-12.7 to -4.2)  0.0001 
 
 
 
Table 3: Influence of age (categorized as <50; 50-70; ≥70 years) on indices of 
anticoagulation control, and incidence of hemorrhage 
 
Characteristics 
Age < 50
(n=341) 
Age 50-70
(n=661) 
Age >70 
(n=496) 
PTBR (INR <2) 37.8 ± 28.4 26.6 ± 26.6 24.3 ± 19.8 
PTTR (INR 2-3) 44.6 ± 23.8 52.7 ± 55.3 57.2 ± 20.5 
PTAR (INR >3) 15.4 ± 17.6 19.2 ± 20.9 17.7 ± 15.9 
Number of patients (%) achieving good anticoagulation control 
Poor (PTTR<60) 250 (73.3%) 394 (59.6%) 257 (51.8%) 
Good (PTTR≥60<70) 40 (11.7%) 117 (17.7%) 104 (21.0%) 
Excellent (PTTR>70) 51 (15.0%) 150 (22.7%) 135 (27.2%) 
Major hemorrhage 
Number of events 20 78 75 
Follow-up (years) 363.1 925.3 761.5
Incidence (95% CI) 5.5 [3.5, 8.4] 8.4 [6.7, 10.5] 9.8 [7.8, 12.3] 
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Figure legends 
 
Figure 1a. Percent time spent below, in, and above target INR range of 2.0-3.0 by warfarin users 
across the three age groups. 
 
Figure 1b. Proportion of patients achieving poor, good, and excellent anticoagulation control by 
warfarin users across the three age groups.  
 
Figure 1c. Time to major hemorrhage across the three age groups. 
Estimated survival curve from Cox proportional hazards model adjusted for race, gender, BMI, 
hypertension, chronic kidney disease, PTTR (<60% vs. ≥60%), concurrent antiplatelet, amiodarone 
and statin medications, and CYP2C9 genotype (note: y axis starts at 0.5) 
 
 
Figure 1a. 
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Figure 1b. 
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Figure 1c. 
 
 
 
 
0.5
0.55
0.6
0.65
0.7
0.75
0.8
0.85
0.9
0.95
1
0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750
Age Less than 50 years
Age 50 to 70 years
Age greater than 70 years
Pr
op
or
tio
n 
of
 p
at
ie
nt
s w
ith
ou
t m
aj
or
 h
em
or
rh
ag
e
Time (days)
